The stock has a market capitalization of $3.06 billion and a price-to-earnings ratio of 41.24. Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, November 3rd. The company reported $0.41 EPS for the quarter, beating the …
Mideast Times · 11/4/2015
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta …
Smallcap Network · ByJohn Udovich · 2/20/2014
It seems possible that the same error took place again. Either way, the resolution of this matter will hold MYGN stock hostage. Either it is an error and MYGN will trade up as soon as it's cleared up, or it isn't an error and MYGN is likely to trade lower ...
Seeking Alpha · ByPaulo Santos · 12/6/2013
MYGN stock closed at $38.48 and was trading above the 100-day moving average. MYGN has a weight of 0.97% in XBI’s portfolio. Clovis Oncology (CLVS) fell 18.39% but still continued to trade above the 100-day moving average. The stock closed at $93.
Market Realist · 9/30/2015
Myriad Genetics (NASDAQ:MYGN) VP Gary A. King sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $42.82, for a total value of $428,200.00. Following the transaction … · 10/30/2015
Myriad Genetics (NASDAQ:MYGN) Director Heinrich Dreismann sold 60,000 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $44.44, for a total value of $2,666,400.00. Following the sale, the ... · 11/10/2015
Myriad Genetics, Inc. (Nasdaq: MYGN) announced that its Board of Directors has approved a two-for-one split of the Company's common stock, effected in the form of a stock dividend. The stock dividend is payable on March 25, 2009 to shareholders of …
StreetInsider · 2/24/2009
Myriad Genetics (MYGN) shares were up more than 11% yesterday to close at a 52-week high of $35.03 yesterday, after the company published data in the Journal of Urology proving that its recurring prostate cancer detection test, Prolaris, yielded positive ... · 2/19/2014
Gene-testing company Myriad Genetics (MYGN) jumped to a five-year high in morning trading in the stock market today after it revealed late Tuesday that the U.S. government is paying a heftier reimbursement for its main test than previously feared.
Investors Business Daily · ByAmy Reeves · 4/2/2014
Myriad Genetics, Inc. (Nasdaq:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Mark C. Capone, President and Chief ...
Stockhouse · 9/11/2015